Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:59:30 2024-05-15 pm EDT			5-day change	1st Jan Change
1.57 ^CAD	-3.09%		-3.09%	-12.29%

May. 15	Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial	MT
May. 15	Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	MT

Oncolytics Biotech Inc. Appoints Matt Coffey as President and Chief Executive Officer

January 19, 2017 at 06:30 am EST

Oncolytics Biotech Inc. announced that Matt Coffey PhD, MBA, has been appointed to the role of President and Chief Executive Officer, effective immediately. Dr. Coffey had been serving as the company's Interim President and Chief Executive Officer since early November 2016.

Latest news about Oncolytics Biotech Inc.

Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial	May. 15	MT
Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	May. 15	MT
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA	May. 13	MT
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million	May. 09	MT
Transcript : Oncolytics Biotech Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Oncolytics Biotech Brief: Q1 Basic and diluted loss per common share $0.09	May. 09	MT
Oncolytics Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer	May. 09	MT
Oncolytics Biotech Brief: Says Received Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer	May. 09	MT
Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer	May. 09	CI
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	Apr. 11	CI
Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA	Apr. 11	MT
Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	Apr. 11	MT
RBC Reiterates Positive Outlook For Oncolytics -- Maintains $6 Target, Outperform/Speculative Risk Rating	Mar. 08	MT
Transcript : Oncolytics Biotech Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain	Mar. 07	MT
Oncolytics Biotech Brief: Q4 Net loss for the fourth quarter of 2023 was $3.9 million	Mar. 07	MT
Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms	Mar. 07	DJ
Oncolytics Biotech Inc. Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	Mar. 05	CI
Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	Mar. 05	MT
Oncolytics Biotech Brief: Says Filed Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	Mar. 05	MT
Oncolytics Biotech Initiating Enrollment Expansion of GOBLET Anal Cancer Cohort	Feb. 14	MT
Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort	Feb. 14	CI
Oncolytics Biotech Brief: Initiating Enrollment Expansion of GOBLET Anal Cancer Cohort	Feb. 14	MT

Chart Oncolytics Biotech Inc.

Duration

Period

More charts

Company Profile

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Companyâs primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Sector

Biotechnology & Medical Research

Calendar

2024-05-23 - American Society of Clinical Oncology Meeting - Abstract Number: e14625

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.57 CAD

Average target price

6.625 CAD

Spread / Average Target

+321.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ONCOLYTICS BIOTECH INC.	-12.29%	89.51M
MODERNA, INC.	+29.77%	49.18B
IQVIA HOLDINGS INC.	+1.00%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.71B
BIO-TECHNE CORPORATION	+8.22%	13.26B
MEDPACE HOLDINGS, INC.	+32.41%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.99B

Other Biotechnology & Medical Research